Effect of Brain-computer Interface on Upper-limb Motor Function after Stroke: A Meta-analysis / 中国康复理论与实践

Objective:To systematically evaluate the effect of brain-computer interface (BCI) on upper-limb motor function after stroke, and compare the effects under different interfaces. Methods:Randomized controlled trials (RCTs) about BCI for upper-limb motor function after stroke were retrieved from databases of PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang Data and CBM, from inception to October, 2020. The quality of the trials was assessed and the data were extracted according to the Cochrane Handbook of Systematic Review. A meta-analysis was carried out with RevMan 5.3 and ADDIS 1.16.8. Results:Ultimately, 14 RCTs involving 504 patients were included. Meta-analysis showed that BCI could obviously improve the Fugl-Meyer Assessment-Upper Extremities (FMA-UE) score (MD = 6.81, 95%CI 1.51 to 12.11, P < 0.05), Action Research Arm Test score (MD = 7.68, 95%CI 0.49 to 14.88, P < 0.05) and modified Barthel Index score (MD = 8.91, 95%CI 5.57 to 12.25, P < 0.001) after stroke. Subgroup analysis showed that FMA-UE score could be improved by BCI for both more than four weeks (MD = 9.44, 95%CI 1.83 to 17.04, P < 0.05) and less than four weeks (MD = 5.18, 95%CI 2.84 to 7.51, P < 0.001). For the types of interface, the probabilities of the best effects from network meta-analysis ranked as electrical stimulator (P = 0.53), visual feedback (P = 0.41) and machine assistance (P = 0.06). Conclusion:BCI, especially with electrical stimulator interface, could obviously improve upper-limb motor function and activities of daily living for stroke patients.

Effect of Banxia Xiexin Decoction on intestinal flora of mice with ulcerative colitis induced by dextran sodium sulfate / 中国中药杂志

The aim of this paper was to investigate the effect of Banxia Xiexin Decoction(BXD) on inflammatory factors and intestinal flora in a dextran sulfate sodium induced ulcerative colitis(DSS-UC) mouse model, and to explore the mechanism of BXD in treating ulcerative colitis from the perspective of flora disorder. Forty C57 BL/6 J mice were randomly divided into control group, model group and BXD group. A 2.5% DSS-induced ulcerative colitis model was established. On the 8 th day, normal saline, normal saline, and BXD were given daily for 14 days. After 14 days, HE staining was used to observe histopathological changes of the colon. Serum inflammatory factor content was detected by ELISA, and the change of intestinal flora in mice feces was detected by 16 S rRNA sequencing technology. Compared with control group, the colonic tissue of mice in model group was damaged seriously, and the contents of IL-6 and TNF-α in serum were significantly increased(P<0.05). Compared with model group, mice in BXD group had less colonic damage, and the contents of IL-6, TNF-α in serum were decreased significantly(P<0.05). After creation, the richness of Patescibacteria was increased significantly at the phylum level(P<0.05). At the same time, the richness of Faecalibaculum(P<0.01), norank_f_Muribaculaceae(P<0.01) were decreased significantly at the genus level, while the richness of Turicibacter(P<0.01), Romboutsia(P<0.01), Clostridium_sensu_stricto_1(P<0.01) were increased significantly. After the intervention with BXD, the content of Patescibacteria was significantly reduced at the phylum level(P<0.05), and the contents of Lactobacillus(P<0.01), Clostri-dium_sensu_stricto_1(P<0.01), Enterorhabdus(P<0.01), Candidatus_Saccharimonas(P<0.05), Eubacterium_fissicatena_group(P<0.05) were decreased significantly at the genus level, while the contents of Dubosiella, Bacteroides and Allobaculum were increased significantly. Therefore, BXD could significantly improve the symptoms of DSS-UC mice. It not only could reduce the contents of IL-6 and TNF-α, but also could reduce the richness of Patescibacteria at the phylum level, and those of Clostridium_sensu_stricto_1, Candidatus_Saccharimonas, Eubacterium_fissicatena_group at the genus level. Inaddition, BXD could increase the richness of Bacteroides and Bifidobacterium. It suggested that BXD could play a role in the treatment of ulcerative colitis partially through reducing inflammatory factors and regulating the structure of the gut microbiota.

Network Meta-analysis of Chinese patent medicines in treatment of liver stagnation and spleen deficiency of depression / 中国中药杂志

To evaluate the clinical efficacy and safety of Shugan Jieyu Capsules,Jieyu Pills and Xiaoyao Pills in the treatment of liver-stagnation and spleen-deficiency depression by the network Meta-analysis( NMA),so as to provide evidence-based clinical practice. Chinese databases,including CNKI,VIP,Wan Fang Data,CBM as well as English databases including the Cochrane Library,PubMed,EMbase and Web of Science were retrieved from inception to October 30,2018,to collect randomized controlled trials( RCTs) about clinical study of the three kinds of Chinese patent medicines. The quality and bias risk of the included studies were assessed by 5. 1 standard in Cochrane Handbook,ADDIS software was applied in the statistical analysis,and the result were compared by NMA. A total of 37 studies involving 3 105 patients were included. The results of NMA showed that the adjuvant therapy with the three kinds of traditional Chinese patent medicines could improve the clinical efficacy. Jieyu Pills had the most significant effect( OR = 4. 59,95%CI[1. 94,12. 71],P<0. 05). In HAMD,Shugan Jieyu Capsules( MD = 3. 22,95%CI[2. 07,4. 39],P< 0. 05) and Xiaoyao Pills( MD= 2. 23,95%CI[0. 41,4. 03],P<0. 05) can effectively reduce the depression scale indicators. In the incidence of adverse reactions,the three kinds of Chinese patent medicines can reduce the incidence of adverse reactions. The three kinds of Chinese patent medicines can be combined with auxiliary Western medicine to treat liver-stagnation and spleen-deficiency depression,with complementary advantages in action mechanisms. In the clinical efficacy and safety,the Chinese patent medicines had good clinical manifestations. Although this study showed that Jieyu Pills may be the referred medicine for depression,this conclusion is still immature and needs to be further verified by high-quality RCTs studies,and the application shall be selective based on specific characteristics in clinic.

Mechanism of Sishenwan in Treatment of Ulcerative Colitis Based on Network Pharmacology and Bioinformatics / 中国实验方剂学杂志

Objective:To investigate the mechanism of Sishenwan in the treatment of Ulcerative Colitis and to explore the key targets and signal pathway on the treatment of Ulcerative Coltis based on network pharmacology and bioinformatics. Method:To obtain the active ingredients and predicted target genes of Sishenwan by searching the Encyclopedia of Traditional Chinese Medicine(ETCM) database, from the Gene Expression Omnibus (GEO) database and Database of Gene-disease Associations (DisGeNET), Online Mendelian Inheritance in Man (OMIM), Drug-targetDatabase (DrugBank), The Comparative Toxicogenomics Database (CTD) and Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) disease database collection of Ulcerative Colitis target genes, the drug-disease protein target gene was obtained by intersecting the two and to display the results by Cytoscape software, through the algorithm of network topology to screen out the key target genes, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were carried out on key target genes using Gene Ontology Enrichment Analysis Softword Toolkit (GOEAST) and The Database for Annotation, Visualization and Integrated Discovery (DAVID) online tools, analyze the mechanism of Sishenwan in preventing and treating Ulcerative Colitis combined with relevant literature. Result:There are 182 active ingredients and 611 predicted targets in Sishen Wans, 914 known disease targets related to the occurrence and development of Ulcerative Colitis were retrieved through the disease database, it was concluded that the effect of Sishenwan on Ulcerative Colitis mainly involves steroid hormone-mediated signal pathway, exogenous metabolic process, positive regulation of transcription of RNA polymerase II promoter, lipid metabolic process, detoxification of cell oxidant, signal transduction and other biological functions, and participates in arachidonic acid, drug metabolism-cytochrome P450, cytochrome P450 for xenobiotics, chemical carcinogenesis and other key signal pathways. Conclusion:Sishenwan has the characteristics of multi-target, multi-channel and multi-level in the treatment of Ulcerative Colitis. Its multiple signal pathways are directly or indirectly related, participating in lipid protein metabolism, drug metabolism and anti-cancer mechanism, etc. It exerts its efficacy through comprehensive intervention on the digestive system, circulatory system, immune system and other multiple systems of the body, thus being consistent with the comprehensive effect mechanism of Ulcerative Colitis induced by multiple factors.